Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xeomin incobotulinumtoxinA Chronic sialorrhea associated with neurological disorders Reimburse with clinical criteria and/or conditions Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Blepharospasm List in a similar manner Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Cervical Dystonia List in a similar manner Complete
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Spasticity, Post-stroke Do not list Complete
Xermelo telotristat carcinoid syndrome Do not reimburse Complete
XGEVA Denosumab Prevention of skeletal-related events due to bone metastases from solid tumours List with clinical criteria and/or conditions Complete
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from breast cancer List with clinical criteria and/or conditions Complete
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer List with clinical criteria and/or conditions Complete
Xiaflex Collagenase clostridium histolyticum Dupuytren’s contracture List with criteria/condition Complete
XigDuo dapagliflozin/metformin hydrochloride Diabetes Mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete